Survival analyses according to type of lymphoma.

(A) Overall survival in 38 patients with relapsed indolent lymphomas (thin solid line) and 14 patients with relapsed aggressive lymphomas (short dashes) treated with ¹³¹I-tositumomab, etoposide, cyclophosphamide, and ASCT and in 44 patients with relapsed indolent lymphomas (thick solid line) and 60 patients with relapsed aggressive lymphomas (long thick dashes) treated with external-beam TBI (1.5 Gy twice a day for 4 days), etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and ASCT. (B) Progression-free survival in 38 patients with relapsed indolent lymphomas (thin solid line) and 14 patients with relapsed aggressive lymphomas (short dashes) treated with¹³¹I-tositumomab, etoposide, cyclophosphamide, and ASCT and in 44 patients with relapsed indolent lymphomas (thick solid line) and 60 patients with relapsed aggressive lymphomas (long thick dashes) treated with external-beam TBI (1.5 Gy twice a day for 4 days), etoposide (60 mg/kg), cyclophosphamide, (100 mg/kg) and ASCT.